Tyrus Soares, MD
Pain Medicine · Omaha, NENPI 1154348191
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,993 of the $8,418 with a category attached, or 71.2%. Medtronic accounts for 63.4% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2022 at $3,109 and has fallen 78.8% since, to $659 in 2025.
Across 183 payments — averaging $46.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Abbott$679
- Stryker$280
- Boston Scientific$256
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$189
- Collegium Pharmaceutical, Inc.$186
- plus $1K from 25 others
What the payments were for
- Travel & lodging$2,42529%
- Food & beverage$5,99371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 44 | $5,337 |
| Abbott | 10 | $679 |
| Stryker | 7 | $280 |
| Boston Scientific | 14 | $256 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $189 |
| Collegium Pharmaceutical, Inc. | 11 | $186 |
| Vertex | 11 | $183 |
| Nevro Corp. | 9 | $157 |
| AbbVie(2 entities) | 8 | $119 |
| Forte Bio-pharma LLC | 6 | $113 |
| Scilex Pharmaceuticals Inc. | 6 | $98 |
| Si-bone, Inc. | 5 | $98 |
| Biohaven Pharmaceuticals, Inc. | 3 | $97 |
| Lundbeck LLC | 5 | $90 |
| Pfizer | 4 | $71 |
| Tonix Medicines, Inc. | 2 | $55 |
| Biodelivery Sciences International, Inc. | 4 | $53 |
| Azurity Pharmaceuticals, Inc. | 3 | $52 |
| Lilly USA, LLC | 3 | $40 |
| Averitas Pharma Inc. | 2 | $39 |
| Biotronik NRO, Inc. | 1 | $34 |
| GRT US Holding, Inc. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Gilead | 1 | $25 |
| Sentynl Therapeutics, Inc. | 2 | $23 |
| Protega Pharmaceutials Inc | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $12 |
| SPR Therapeutics, Inc | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KYPHON EXPRESS II KYPHOPAK TRAY$2,268
- INTELLIS ADAPTIVESTIM$1,148
- Proclaim Family of SCS IPGs$456
- VANTA ADAPTIVESTIM$443
- INTELLIS$248
- INCEPTIV$175
- SYNCHROMED$138
How this compares
$8,418 in reported general payments places this provider in the 70th percentile of 31 pain medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 119 | $85,884 |
| Buprenorphine | 171 | $37,182 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,164 | $34,900 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 749 | $27,464 |
| OxycontinOxycodone Hcl | 47 | $20,021 |
| Hysingla ErHydrocodone Bitartrate | 26 | $18,654 |
| Gabapentin | 625 | $11,276 |
| Morphine Sulfate ErMorphine Sulfate | 322 | $10,577 |
| Tramadol Hcl | 832 | $9,162 |
| ButransBuprenorphine | 22 | $9,126 |
| Pregabalin | 374 | $8,121 |
| Tizanidine Hcl | 442 | $5,313 |
| Methadone Hcl | 148 | $3,319 |
| Lidocaine | 30 | $2,942 |
| Fentanyl | 32 | $2,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $186 | $85,884119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 31 pain medicine providers in Nebraska.
Other pain medicine in Omaha
- Matthew StottleOmaha$14K
- Katie BerkyOmaha$12K
- Apollo StackOmaha$8K
- Jess RolandOmaha$8K
- Marshall LaddOmaha$7K
- James DevneyOmaha$5K
- Peter PiperisOmaha$4K
- Dan NichollsOmaha$3K
- Ernesto PadronOmaha$3K
- Christopher CriscuoloOmaha$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.